文献速递肺外科

免疫检查点抑制剂治疗后晚期非小细胞肺癌切除术:两中心经验

Two centres experience of lung cancer resection in patients with advanced non-small cell lung cancer upon treatment with immune checkpoint inhibitors: safety and clinical outcomes.
PubMed 文献 · Eur J Cardiothorac Surg · 2021-01-01

术后并发症发生率为27%,90天死亡率为零;II/IIIA期与IIIB/IV期的1年无复发生存率分别为73%和55%,主要病理缓解率为34%。结论认为免疫治疗后肺切除是安全的,尽管常需复杂手术。

要点

  • 免疫检查点抑制剂治疗后肺切除安全,90天死亡率为零。
  • 27%患者出现术后并发症,常需复杂手术方式。
  • 主要病理缓解率34%,IIIB/IV期1年无复发生存率55%。

核心结论

  • 免疫检查点抑制剂治疗后行肺切除是安全的,尽管常需复杂手术。

主要发现

  • 27%患者(10例)出现术后并发症,90天死亡率为零。
  • II/IIIA期1年无复发生存率为73%,IIIB/IV期为55%;主要病理缓解率为34%。

临床怎么用

  • 免疫检查点抑制剂治疗后可为部分晚期非小细胞肺癌患者创造手术机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Recent trials have begun to explore immune checkpoint inhibitors for non-small cell lung cancer in the neoadjuvant setting, but data on tumour response and surgical outcome remain limited. METHODS: Retrospective evaluation of clinical data from patients with non-small cell lung cancer treated with immune checkpoint inhibitors followed by lung resection was performed at 2 large volume institutions (1 North American, 1 European). Data were analysed using Chi-squared, Fisher's and Wilcoxon rank-sum tests where appropriate. RESULTS: Thirty-seven patients were identified from 2017 to 2019. Forty-nine per cent were Stage IIIB and IV. Forty-six per cent received immunotherapy alone and 54% in combination with chemo- and/or radiotherapy. Sixteen per cent of cases were successfully performed minimally invasively. Twenty patients were operated with lobectomy (6 of these with wedges or segments of a neighbouring lobe, 2 with sleeve resections and 1 with a chest wall resection), 4 with bilobectomies, 11 with pneumonectomy (including 5 extrapleural pneumonectomies and 1 atrial resection) and 1 with a wedge resection. Overall, 10 patients (27%) developed postoperative complications and the 90-day mortality was zero. One-year recurrence-free survival was 73% for stage II/IIIA and 55% for stage IIIB/stage IV. The major pathologic response rate was 34%. CONCLUSION: In this retrospective study, lung resection after immunotherapy (alone or in combination) is safe, although often requires complex surgery. Due to increasing number of clinical trials adopting immunotherapy in the neoadjuvant setting, it is likely that this therapy will become part of standard of care. Immunotherapy may also allow surgery to have a role for selected patients with advanced disease.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Beattie R, Furrer K, Dolan DP, et al. Two centres experience of lung cancer resection in patients with advanced non-small cell lung cancer upon treatment with immune checkpoint inhibitors: safety and clinical outcomes. Eur J Cardiothorac Surg. 2021. PMID: 34331065. doi:10.1093/ejcts/ezab340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。